Abstract. Biological characteristics of a tumor are primarily affected by its genomic alterations. It is thus important to ascertain whether there are genomic changes linked with DNA ploidy and/or chromosomal instability (CIN). In the present study, using fresh-frozen samples of 46 invasive breast cancers, laser scanning cytometry, array-based comparative genomic hybridization, and chromosome fluorescence in situ hybridization were performed to assess DNA ploidy, DNA copy number aberrations (DCNAs), and CIN status. Both ploidy and CIN status were examined in 36 tumors, resulting in 23 aneuploid/CIN + tumors, 1 aneuploid/ CIN -, 2 diploid/CIN + , and 10 diploid/CIN -tumors. Comparison of the aCGH data with the DNA ploidy and CIN status identified cytogenetically 11 characteristic breast cancers with distinctive DCNAs. The 11 tumors were classified into two types; one type is diploid/CIN -phenotype containing 4 DCNAs, and the other aneuploid/CIN + phenotype containing 7 DCNAs. In 30 (65.2%) of the 36 breast cancers, the status of DNA ploidy and CIN depended on the type of DCNAs. Furthermore, the DNA ploidy phenotype depended on the dominant type of DCNAs even in tumors with a mixture of multiple DCNAs of one type and a single DCNA of the other type. Tumors with multiple DCNAs of both types represented aneuploidy and over three quarters of breast cancers carry at least one type of the DCNAs. These results suggested that, in breast cancers, the status of DNA ploidy and CIN was likely to determine at the beginning of carcinogenesis.
Introduction
Cancer cells possess extensive genomic alterations, ranging from intragenic mutations, to gross gains and losses of chromosomal material (1, 2) . Aneuploidy, an alteration in the number of chromosomes or nuclear DNA content, is a common trait of tumor cells, and it drives tumor progression (3) . With tumor progression, aneuploidy successively confers a more aggressive character to tumor cells (4) . Thus, aneuploidy has been used as a prognostic marker of various kinds of cancers including breast cancer (5) (6) (7) .
Genomic instability is also recognized as inherent characteristics of cancer cells. The underlying mechanisms of genomic instability are different among tumors. Genomic instability is roughly divided into microsatellite instability (MIN) and chromosomal instability (CIN) (8) . CIN affords tumor cells the ability to make continual changes in their chromosome numbers and structures with deletions and amplifications of chromosomal regions, and as a result, it provides cancer cells with further structural and numerical abnormalities of chromosomes (8) (9) (10) (11) .
A close relationship has been suggested between aneuploidy and CIN (8, 9) . Aneuploidy and CIN usually coexist in tumor cells (8) and aneuploidy is considered to be a surrogate marker of CIN (9) . However, aneuploidy is conceptually different from CIN (9) . In normal cells, both ploidy and genomic stability are strictly maintained, and are rigorously controlled by complex mechanisms with hundreds of genes related to mitosis and DNA repair. The defects of the mechanisms potentially cause abnormal mitosis and genetic alterations, leading to aneuploidy and/or genomic instability (12) . There are multiple mechanisms to confer aneuploidy and CIN on a tumor cell (13) . Tumor phenotype including aneuploidy and genomic instability is thus primarily affected by their genomic changes.
The identification of genomic changes associated with aneuploidy and CIN is crucial to elucidate the evolutional mechanisms of aneuploidy and CIN. However, information on the relationship between genomic alterations and the status of ploidy and genomic instability is scarce. First, a comprehensive analysis of genomic changes in tumors is necessary, because tumors with aneuploidy or CIN represent genomic abnormalities at many chromosomal regions. Genomic alterations such as DNA copy number aberrations (DCNAs) linked with the status of DNA ploidy and CIN have not been identified. In particular, it is necessary to clarify whether there are genomic aberrations that differ between diploid and aneuploid tumors, and between CIN -and CIN + tumors, and whether there are any genomic alterations that are shared by aneuploidy and CIN + . In the present study, we identified DCNAs associated with both aneuploidy and CIN in breast cancers, and the DCNA pattern allowed classification of breast cancers into two types, aneuploid/CIN + and diploid/CIN -tumors. The purpose of the study was to assess the extent of the genomic aberrations observed in tumors with aneuploidy and CIN, and to gain insight into the evolutional mechanisms of aneuploidy and CIN in tumors.
Materials and methods
Tumor tissue specimens. The present study analyzed 46 primary invasive breast cancers. All tumors were considered to be sporadic. The average age of the patients was 57.6 years, ranging from 31 to 75 years. None of the patients had received either chemotherapy or radiation prior to surgery. The Institutional Review Board for human tissue use at Yamaguchi University Graduate School of Medicine approved the study protocol, and informed consent for this study was obtained from all the patients. A representative part of the surgically removed tumor tissue specimens was used for touch-smear preparations before fixation. The tumor tissue specimens were fixed in 10% buffered formalin for one day and then were subjected to a histological examination including an immunohistochemical study. The touch-smear preparations were subjected to fluorescence in situ hybridization (FISH) and laser scanning cytometry (LSC).
FISH and assessment of CIN. CIN was examined by fluorescence in situ hybridization (FISH) using 4 pericentromeric probes (chromosomes 7, 11, 17, and 18 for D7Z1, D11Z1, D17Z1, and D18Z1, respectively; Abbott Laboratories. Abbott Park, IL) on the touch-smear preparations in 36 of 46 tumors as described previously (14) (15) (16) , and the presence or absence of CIN was determined according to the degree of variations in the number of FISH spots between nuclei (14-16). The tumors were considered to be CIN positive (CIN+) when the fraction of cells with modal chromosome number was <75% for four chromosomes.
DNA ploidy determination. Measurement of nuclear DNA content by LSC was performed in 46 breast cancer specimens. Samples were made and DNA ploidy was determined by the procedures described previously (14, 15) . Briefly, the touch-smear preparations fixed in 70% ethanol were dipped in a propidium iodide solution (25 μg/ml in PBS) containing 0.1% RNase (Sigma-Aldrich Co., St. Louis, MO). The DNA content was measured by a laser scanning cytometer (LSC 101; Olympus, Japan). In each touch smear sample >5,000 cells were examined. A DNA histogram was generated, and DNA ploidy was determined. DNA ploidy was expressed by the DNA index (DI). A case with 1.0≤DI<1.2 was classified as a diploid, and others were classified as aneuploid tumors (14, 15) .
Array-based comparative gemonic hybridization. Arraybased comparative genomic (aCGH) was performed for 46 breast cancers. A tissue microdissection technique was used to reduce the contamination of samples by normal tissue components for aCGH analyses, as previously described (17) . The normal cell contamination of the samples was reduced as much as possible, and it was usually <10%. High-molecular-weight DNA was extracted from each microdissected tumor specimen with a DNA extraction kit (SepaGene, Sankojyunyaku Co., Tokyo, Japan) according to the manufacturer's instructions. The BAC DNA array used in this study consists of 4030 human bacterial artificial chromosome (BAC) clones, including 356 cancer-related genes, which are spaced ~0.83 Mb across the whole genome (Macrogen, Inc., Seoul, Korea). BAC chip information is available on the following websites (http://www.macrogen. co.kr/eng/biochip/karyo_summary.jsp).
The experiments were performed as previously described (18) (19) (20) . Briefly, tumor DNA (500 ng) and gender-matched reference DNA (Promega, Madison, WI) were labeled with Cy5-and Cy3-dCTP (Perkin-Elmer Life Science, Inc., Waltham, MA), respectively, with a random primer labeling kit (BioPrine ® DNA Labelling System, Invitrogen, Carlsbad, CA). Labeled DNA was mixed with Cot-1 DNA (50 mg, Gibco-BRL, Gaithersburg, MD) and the probe mixture that was denatured at 75˚C was applied to the array. After hybridization, slides were scanned on a GenePix 4000A scanner (Axon Instruments, Union City, CA) and the 16-bit TIFF images captured using GenePix Pro 5.0 software. Fluorescence images were analyzed with MAC Viewer™ software (Macrogen Inc.) optimized for analysis of the array. Fluorescence spots were defined with the automatic grid feature and adjusted manually. Thereafter the ratio of the red/green channel of each clone was calculated log base 2 transformed (log 2 ratios). The clones with log 2 ratios exceeding ±0.25 were considered gain and loss of the copy number. A log 2 ratio >1.0 was defined as amplifications in this study (18) (19) (20) .
Statistical analysis.
A clone-by-clone comparison of the copy number was made between the cell lines and tumor tissues. The differences in the prevalence of common gains and losses between two groups were determined with the ¯2 test. A difference was considered to be significant when the p-value was <0.05. aCGH. DCNAs were examined in 46 tumors. Gains of 1q and 8q, and losses of 8p, 16q, and 17p were detected in >50% of 46 tumors (Fig. 1) . BAC clones mapped to the broad area 1q23-q44 represented the highest frequency of copy number gains, and in particular, the gain of 1q32.1 (clone 2893) was detected in 78.3% of 46 tumors (Table IA) (Table IB) .
Results

DNA
aCGH vs. DNA ploidy. DCNAs were observed to be linked with the DNA ploidy status as shown in Table II DCNAs that were associated with both the DNA ploidy and CIN status. At least one of these DCNAs was detected in 34 tumors, though none of these DCNAs were detected in one diploid/CIN -tumor and one aneuploid/CIN + tumor (Table IV) .
Four DCNAs composed of gains of 1q31.1, 1q21.1, and 1q24.2 and loss of 16q23.1 were more frequent in diploid/CIN -than in aneuploid/CIN + tumors (7/10 vs. 5/23, 7/10 vs. 1/23, 7/10 vs. 4/23, and 7/10 vs. 3/23, respectively, Table IV ). One to 4 of these DCNAs were observed in the 10 diploid/CIN -tumors and in both of the 2 diploid/CIN + tumors (Table IV) . Accordingly, these genomic alterations are conveniently referred to as 'diploid/CIN -DCNAs'. The 'diploid/ CIN -DCNAs' were also observed in some of the aneuploid/CIN + tumors (Table IV) Table I . Clones representing frequent copy number gain and loss in 46 breast cancers.
Clones representing frequent copy number gain. 
Clones representing frequent copy number loss. 
-----------------------------------------------------------------------------------------------------
N.I., not identified.
- -------------------------------------------------------------------------------------------------- Table II . Clones with significant difference in frequency of copy number loss between diploid and aneuploid breast cancers.
-----------------------------------------------------------------------------------------------------Copy number gain Copy number loss -----------------------------------------------------------Frequency Frequency Clone Chromosome -----------------
Clone Chromosome ----------------ID region Diploid Aneuploid P-value ID region Diploid Aneuploid P- value  ---------------------------------------------------------------------------------------------------- Table III . Clones with significant difference in frequency of copy number loss between CIN positive and negative breast cancers.
-----------------------------------------------------------------------------------------------------
Copy number gain Copy number loss Table IV . BAC clones of which DNA copy number aberrations are associated with ploidy/CIN status. 
Discussion
DNA aneuploidy is frequently observed in malignant tumors, and it accounts for two thirds of breast cancers (21) (22) (23) . In this study, the frequency of aneuploidy was 67.4%, and this is consistent with the previous data. Although aneuploidy is not equated with CIN, aneuploidy is recognized as a surrogate marker of CIN (8, 9) . The present study revealed that aneuploid tumors frequently overlapped with CIN The present aCGH study allowed for the identification of 11 DCNAs with a differing frequency between diploid and aneuploid cancers and between CIN -and CIN + cancers. Of these DCNAs, 4 were linked with a diploid/CIN -phenotype, whereas 7 were linked with an aneuploid/CIN + phenotype. Breast cancers were divided into two categories according to the combination of these two DCNA types; tumors with either one type of DCNAs or the other, and tumors with both types of DCNAs. In 30 (65.2%) breast cancers with either one type of DCNAs or the other, the phenotypic status of Therefore, it is legitimate to consider that some aneuploid tumors (5 tumors in this series) occur through diploid ones during the course of tumor progression. However, diploid tumors do not occur through aneuploid ones, because aneuploidy is a dominant phenotype. In other words, around 10% of aneuploid tumors evolve through diploid tumors. Aneuploid/ CIN + tumors can therefore be divided into two types; ab initio aneuploid/CIN + and secondary aneuploid/CIN + tumors. The developmental rate of a diploid tumor may thus be similar to that of aneuploid tumors, but the diploid-to-aneuploid transition in tumors makes the diploid/aneuploid tumor ratio around1/2 as shown in clinical samples.
Genomic instability is roughly divided into microsatellite instability (MIN) and CIN, which are considered to be the underlying mechanisms responsible for diploidy and aneuploidy, respectively (8, 9, 24, 25) . However, there is little information about genomic alterations implicated in both ploidy and CIN status. Two types of DCNAs, 'diploid/CINDCNAs' and 'aneuploid/CIN + DCNAs' were identified for differentiating diploid/CIN -and aneuploid/CIN + tumors. The identification of DCNAs linked with both ploidy and CIN status raises the hypothesis that there is an evolutional pathway shared by ploidy and CIN status. It is easy to explain why the association between aneuploidy and CIN + is a usual event in tumors, assuming that a common pathway generates both aneuploidy and CIN + . Aneuploidy and CIN + phenotypes are accompanied by checkpoint silencing (26, 27) and are generated by genetic aberrations targeting components of mitotic process (26) (27) (28) (29) , and there are genes encoding modulators of genomic and mitotic stability (30) (31) (32) . If the chromosomal regions with these DCNAs harbor genes modulating whole suites of downstream genes at various points in pathways for the maintenance of genome and chromosome, it is not difficult to suppose that the DCNAs would affect genomic and mitotic stability. When at least 1 of 7 'aneuploid/CIN + DCNAs' is added to the basic genomic changes in a tumor cell, the cell ends up showing aneuploidy and CIN + phenotype. It is not yet possible to identify which genes on these chromosomal regions with DCNAs are involved in the status of ploidy and CIN, nor is it possible to explain how the genes are involved in the status of ploidy and CIN.
In conclusion, the present study revealed 11 DCNAs linked with the status of ploidy and CIN in breast cancers. Four DCNAs were linked with the diploid/CIN -phenotype, whereas 7 DCNAs were linked with the aneuploid/CIN + phenotype. These two types of DCNAs represented a mutually exclusive relationship between diploid and aneuploidy and between the CIN -and CIN + phenotypes. In particular, the identification of these 7 DCNAs may thus provide valuable new insights into the mechanism behind the development of aneuploidy/CIN + . The present CGH study may contribute to the discovery a novel pathway for the aneuploidy/CIN + phenotype. Further research is required to elucidate this new mechanism for aneuploidization and CIN.
